FOXO Technologies Inc. (FOXO)
- Previous Close
0.2811 - Open
0.2786 - Bid 0.2770 x 2900
- Ask 0.2880 x 1000
- Day's Range
0.2705 - 0.2970 - 52 Week Range
0.2500 - 5.2800 - Volume
215,865 - Avg. Volume
1,118,503 - Market Cap (intraday)
2.527M - Beta (5Y Monthly) 1.76
- PE Ratio (TTM)
0.01 - EPS (TTM)
37.1700 - Earnings Date Apr 29, 2024 - May 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
FOXO Technologies Inc. engages in epigenetic biomarker underwriting technology and consumer engagement platform service business in the United States. It operates through two segments, FOXO Labs and FOXO Life. The company applies automated machine learning and artificial intelligence technologies to discover epigenetic biomarkers of human health, wellness, and aging. It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and FOXO Life, a sales and distribution platform focused on recruiting independent life insurance agents to sell life insurance with the Longevity Report. The company was founded in 2020 and is based in Minneapolis, Minnesota. FOXO Technologies Inc. is a subsidiary of FOXO Management LLC.
foxotechnologies.com4
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: FOXO
Performance Overview: FOXO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FOXO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FOXO
Valuation Measures
Market Cap
2.53M
Enterprise Value
6.49M
Trailing P/E
0.01
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.99
Price/Book (mrq)
--
Enterprise Value/Revenue
14.33
Enterprise Value/EBITDA
-0.17
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-61.53%
Return on Equity (ttm)
-1,754.50%
Revenue (ttm)
453k
Net Income Avi to Common (ttm)
-43.38M
Diluted EPS (ttm)
37.1700
Balance Sheet and Cash Flow
Total Cash (mrq)
42k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-26.96M